Erythrasma
ICD-10 L08.1 is a billable code used to indicate a diagnosis of erythrasma.
Erythrasma is a superficial skin infection caused by the bacterium Corynebacterium minutissimum, primarily affecting intertriginous areas such as the groin, axillae, and between the toes. Clinically, it presents as well-defined, reddish-brown patches with a fine scale, often mistaken for other dermatological conditions like tinea cruris or psoriasis. The condition is more prevalent in warm, humid climates and among individuals with diabetes or obesity due to increased skin friction and moisture. Disease progression is typically slow, and while erythrasma is not contagious, it can persist if left untreated. Diagnosis is primarily clinical, supported by Wood's lamp examination, which reveals a coral-red fluorescence in affected areas, and can be confirmed through culture or skin scraping. Treatment usually involves topical antibiotics such as clindamycin or erythromycin, and in more severe cases, oral antibiotics may be necessary. Regular follow-up is essential to monitor for recurrence, especially in patients with predisposing factors.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
L08.1 specifically covers erythrasma, a bacterial skin infection characterized by reddish-brown patches, primarily affecting intertriginous areas. It is important to differentiate it from fungal infections and other dermatoses.
L08.1 should be used when the diagnosis is confirmed as erythrasma, particularly when clinical presentation and diagnostic tests (like Wood's lamp) support this specific condition, differentiating it from tinea or other skin infections.
Documentation should include a detailed clinical description of the lesions, results from diagnostic tests (such as Wood's lamp examination), and treatment plans. Follow-up notes indicating the response to treatment are also essential.
